PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has reported significant progress in its Q2 2024 update, with major advancements in its lead drug program for Retinitis Pigmentosa type 11, including establishing safety and early human efficacy. The company is on track to initiate human trials for three drugs with the potential to treat genetic diseases without current treatment options by the end of 2024. Key milestones include gaining Orphan Drug Designation from the FDA and progressing towards human trials for Autosomal Dominant Optic Atrophy and Polycystic Kidney Disease.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
